Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4030 | Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 Wiki | 1.00 |
| drug3424 | SARS-CoV-2 and/or MIS-C Exposure Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.
Description: Average increase in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.
Measure: Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3. Time: Day1 and Day3.Description: Percentage of patients per group with progression of pneumonia in Day3, Day 7 and Day28
Measure: Progression of pneumonia Time: Day3, Day7 and Day28Description: Proportion of patients with PaO2 / FiO2 <300 (or SatO2 / FiO2 ≤315) at some point in the evolution.
Measure: PaO2/FiO2 Time: Day3, Day7 and Day28Description: cause mortality to 28 days after started treatment
Measure: cause mortality to 28 days after started treatment Time: Day3, Day7 and Day28Description: Length of hospital stay
Measure: Length of hospital stay Time: Day3, Day7 and Day28Description: Percentage of patients requiring Intensive Care Unit admission
Measure: patients requiring Intensive Care Unit admission Time: Day3, Day7 and Day28Description: IL-12 levels at Day 7
Measure: evolution of inflammatory parameters IL12 Time: Day0, Day3 and Day7Description: IL-10, IL-1, IL-6, IL-17 and IFN-gamma levels on days Day 0, Day1, Day 3 and Day 7
Measure: evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma Time: Day0, Day3 and Day7Description: Procalcitonin (PCT), levels on days Day0, Day1, Day3 and Day 7 7
Measure: evolution of inflammatory parameters Procalcitonin (PCT), Time: Day0, Day3 and Day7Description: C-reactive protein (PCR),levels on days Day0, Day1, Day3 and Day 7 7
Measure: evolution of inflammatory parameters C-reactive protein (PCR), Time: Day0, Day3 and Day7Description: D-dimer levels on days Day0, Day1, Day3 and Day 7 7
Measure: evolution of inflammatory parameters D-dimer Time: Day0, Day3 and Day7Description: ferritin levels on days Day0, Day1, Day3 and Day 7 7
Measure: evolution of inflammatory parameters and ferritin Time: Day0, Day3 and Day7Description: Cmin,on Day0, Day1, Day3 and Day7. On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
Measure: pharmacokinetics of tocilizumab Cmin Time: Day0, Day1 Day3 and Day7Description: Cmax,on Day0, Day1, Day3 and Day7. On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
Measure: pharmacokinetics of tocilizumab Cmax Time: days Day0, Day1 Day3 and Day7Description: Cmedia,on Day0, Day1, Day3 and Day7. On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
Measure: pharmacokinetics of tocilizumab Cmedia Time: days Day0, Day1 Day3 and Day7Description: Tmax,on Day0, Day1, Day3 and Day7. On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
Measure: pharmacokinetics of tocilizumab Tmax Time: days Day0, Day1 Day3 and Day7Description: AUC,on Day0, Day1, Day3 and Day7. On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
Measure: pharmacokinetics of tocilizumab AUC Time: days Day0, Day1 Day3 and Day7Description: Serious and non-serious adverse events.
Measure: Adverse event Time: days Day0, Day3, Day7 and Day28Description: Adverse events to cause the treatment interruption.
Measure: Adverse event to cause the treatment interruption. Time: days Day0, Day3, Day7 and Day28Description: Abnormalities in laboratory findings unrelated to COVID-19 disease.
Measure: Adverse event Abnormalities in laboratory Time: days Day0, Day3, Day7 and Day28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports